The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat

NeuroToxicology

Volumn 29, Issue 6, 2008, Pages 1100-1106

  Kagiava, Alexia ^a   Tsingotjidou, Anastasia ^b   Emmanouilides, Christos ^c   Theophilidis, George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c INTERBALKAN MEDICAL CENTER   (Greece)

Author keywords

Channels; Fibres; In vitro; Neurotoxicity; Oxaliplatin; Potassium; Rat; Sciatic nerve; Voltage gated

Indexed keywords

4 AMINOPYRIDINE; LIDOCAINE; OXALIPLATIN; TETRYLAMMONIUM; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ACTION POTENTIAL; AFTERHYPERPOLARIZATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; MALE; MYELINATED NERVE; NERVE FIBER; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; REPOLARIZATION; SCIATIC NERVE;

ANESTHETICS, LOCAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOPHYSICAL PROCESSES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTRIC STIMULATION; EVOKED POTENTIALS; LIDOCAINE; MALE; ORGANOPLATINUM COMPOUNDS; PIPERIDINES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, VOLTAGE-GATED; RATS; RATS, WISTAR; SCIATIC NERVE; TETRAETHYLAMMONIUM;

RATTUS;

EID: 56249121217     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2008.09.005     Document Type: Article

References (48)

1. + channel kinetics on rat sensory neurons. Eur J Pharmacol 406 (2000) 25-32
2. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343-2351
3. Andreou A., Dabarakis N., Kagiava A., Kosmidis E.K., Geronikaki A., and Theophilidis G. Assessing the effects of three dental impression materials on the isolated sciatic nerve of rat and frog. Toxicol In Vitro 21 (2007) 103-108
4. Baker M., Bostock H., Grafe P., and Martius P. Function and distribution of three types of rectifying channel in rat spinal root myelinated axons. J Physiol (Lond) 383 (1987) 45-67
5. + channels in frog peripheral myelinated axons. Gen Physiol Biophys 25 (2006) 263-276
6. Bowe C.M., Kocsis J.D., and Waxman S.G. Differences between ventral and dorsal spinal roots in response to blockade of potassium channels during maturation. Proc R Soc Lond Ser B 224 (1985) 355-356
7. Bostock H., Sears T.A., and Sherratt R.M. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibers. J Physiol (Lond) 313 (1981) 301-315
8. Brismar T., Sima A.A.F., and Greene D.A. Reversible and irreversible nodal dysfunction in diabetic neuropathy. Ann Neurol 21 (1987) 504-507
9. Cassidy J., and Misset J.L. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 29 (2002) 11-20
10. Castle N.A., Fadous S.R., Logothetis D.E., and Wang G.K. 4-Aminopyridine binding and slow inactivation are mutually exclusive in rat Kv1,1 and Shaker potassium channels. Mol Pharmacol 46 (1994) 1175-1181
11. Chung K.Y., and Saltz L.B. Adjuvant therapy of colon cancer: current status and future directions. Cancer J 13 (2007) 192-197
12. + channels. J Neurophysiol 87 (2002) 1376-1385
13. Eckel F., Schmelz R., Adelsberger H., Erdmann J., Quasthoff S., and Lersch C. Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study. Dtsch Med Wochenschr 127 (2002) 78-82
14. Donzelli E., Carf M., Miloso M., Strada A., Galbiati S., Bayssas M., et al. Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y. J Neuro-Oncol 67 (2004) 65-73
15. Eng D.L., Gordon T.R., Kocsis J.D., and Waxman S.G. Development of 4-AP and TEA sensitivities in mammalian myelinated nerve fibers. J Neurophysiol 60 (1988) 2168-2179
16. 2+-induced injury in CNS white matter. J Neurophysiol 76 (1996) 3264-3273
17. Graham M.A., Lockwood G.F., Greenslade D., Brienza S., Bayssas M., and Gamelin E. Clinical Pharmacokinetics of Oxaliplatin: A Critical Review. Clinical Cancer Research 6 (2000) 1205-1218
18. Grolleau F., Gamelin L., Boisdron-Celle M., Lapied B., Pelhate M., and Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85 (2001) 2293-2297
19. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 30 (2003) 5-13
20. Grothey A., and Goldberg R.M. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother 5 (2004) 2159-2170
21. Hsieh R.K., Chao T.Y., Chen W.S., Yang T.S., Chen L.T., Chen P.M., et al. Oxaliplatin added to simplified bimonthly low-dose leucovorin and 5-FU for pretreated advanced colorectal cancer is effective and not affected by different previous 5-FU regimens. Cancer Invest 22 (2004) 171-179
22. Holmes J., Stanko J., Varchenko M., Ding H., Madden V.J., Bagnell C.R., et al. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. J Toxicol Sci 46 (1998) 342-351
23. Kern W., Braess J., Böttger B., Kaufmann C.C., Hiddemann W., and Schleyer E. Oxaliplatin Pharmacokinetics during a Four-Hour Infusion. Clinical Cancer Research 5 (1999) 761-765
24. + channel function in vivo. Clin Cancer Res 12 (2006) 4481-4484
25. Kocsis J.D., Ruiz J.A., and Waxman S.G. Maturation of mammalian myelinated fibers: changes in action-potential characteristics following 4-aminopyridine application. J Neurophysiol 50 (1983) 449-463
26. Kocsis J.D., Eng D.L., Gordon T.R., and Waxman S.G. Functional differences between 4-aminopyridine and tetraethylammonium-sensitive potassium channels in myelinated axons. Neurosci Lett 75 (1987) 193-198
27. Lehky T.J., Leonard G.D., Wilson R.H., Grem J.L., and Floeter M.K. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29 (2004) 387-392
28. Mert T. Roles of axonal voltage-dependent ion channels in damaged peripheral nerves. Eur J Pharmacol 568 (2007) 25-30
29. Pasetto L.M., D'Andrea M.R., Rossi E., and Monfardini S. Oxaliplatin-related neurotoxicity: how and why?. Crit Rev Oncol Hematol 59 (2006) 159-168
30. Pendyala L., and Creaven P.J. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53 (1993) 5970-5976
31. Pendyala L., Kidani Y., Perez R., Wilkes J., Bernacki R.J., and Creaven P.J. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett 97 (1995) 177-184
32. Papaefthimiou C., Cabral M.D., Mixailidou C., Viegas C.A., Sa-Correia I., and Theophilidis G. Comparison of two screening bioassays, based on the frog sciatic nerve and yeast cells, for the assessment of herbicide toxicity. Environ Toxicol Chem 23 (2004) 1211-1218
33. Poliak S., and Peles E. The local differentiation of myelinated axons at nodes of Ranvier. Nat Rev Neurosci 4 (2003) 968-980
34. Rasband M.N. It's "Juxta" potassium channel!. J Neurosci Res 76 (2004) 749-757
35. Rasband M.N., Trimmer J.S., Schwarz T.L., Levinson S.R., Ellisman M.H., Schachner M., et al. Potassium channel distribution, clustering, and function in remyelinating rat axons. J Neurosci 18 (1998) 36-47
36. Ritchie J.M. A pharmacological approach to the structure of sodium channels in myelinated axons. Annu Rev Neurosci 2 (1979) 341-362
37. Rixe O., Ortuzar W., Alvarez M., Parker R., Reed E., Paull K., et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52 (1996) 1855-1865
38. Schmalbruch H. Fiber composition of the rat sciatic nerve. Anat Rec 215 (1986) 71-81
39. + current regulating excitability in the rat node of Ranvier. J Physiol (Lond) 573 (2006) 17-34
40. Stanfield P.R. Tetraethylammonium ions and the potassium permeability of excitable cells. Rev Physiol Biochem Pharmacol 97 (1983) 1-67
41. Stephens G.J., Garratt J.C., Robertson B., and Owen D.G. On the mechanism of 4-aminopyridine action on the cloned mouse brain potassium channel mKv1,1. J Physiol (Lond) 477 (1994) 187-196
42. Targ E., and Kocsis J.D. Action potential characteristics of demyelinated rat sciatic nerve following application of 4-aminopyridine. Brain Res 363 (1986) 1-9
43. Theophilidis G., Benaki M., and Papadopoulou-Mourkidou E. Neurotoxic action of six pyrethroid insecticides on the isolated sciatic nerve of a frog (Rana ridibunda). Comp Biochem Physiol C 118 (1997) 97-103
44. Tomaszewski A., and Busselberg D. Cisplatin modulates voltage gated channel currents of dorsal root ganglion neurons of rats. Neurotoxicology 28 (2007) 49-58
45. Webster R.G., Brain K.L., Wilson R.H., Jean L., Grem J.L., and Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharm 146 (2005) 1027-1039
46. Wilson R.H., Lehky T., Thomas R.R., Quinn M.G., Floeter M.K., and Grem J.L. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20 (2002) 1767-1774
47. Wolpin B.M., Meyerhardt J.A., Mamon H.J., and Mayer R.J. Adjuvant treatment of colorectal cancer. CA Cancer J Clin 3 (2007) 168-185
48. Yeh J.Z., Oxford G.S., Wv C.H., and Narahashi T. Interactions of aminopyridines with potassium channels of squid axon membranes. Biophys J 16 (1977) 77-81